Literature DB >> 21527570

A 3T MR imaging investigation of the topography of whole spinal cord atrophy in multiple sclerosis.

J P Klein1, A Arora, M Neema, B C Healy, S Tauhid, D Goldberg-Zimring, C Chavarro-Nieto, J M Stankiewicz, A B Cohen, G J Buckle, M K Houtchens, A Ceccarelli, E Dell'Oglio, C R G Guttmann, D C Alsop, D B Hackney, R Bakshi.   

Abstract

BACKGROUND AND
PURPOSE: Spinal cord atrophy is a common feature of MS. However, it is unknown which cord levels are most susceptible to atrophy. We performed whole cord imaging to identify the levels most susceptible to atrophy in patients with MS versus controls and also tested for differences among MS clinical phenotypes.
MATERIALS AND METHODS: Thirty-five patients with MS (2 with CIS, 27 with RRMS, 2 with SPMS, and 4 with PPMS phenotypes) and 27 healthy controls underwent whole cord 3T MR imaging. The spinal cord contour was segmented and assigned to bins representing each C1 to T12 vertebral level. Volumes were normalized, and group comparisons were age-adjusted.
RESULTS: There was a trend toward decreased spinal cord volume at the upper cervical levels in PPMS/SPMS versus controls. A trend toward increased spinal cord volume throughout the cervical and thoracic cord in RRMS/CIS versus controls reached statistical significance at the T10 vertebral level. A statistically significant decrease was found in spinal cord volume at the upper cervical levels in PPMS/SPMS versus RRMS/CIS.
CONCLUSIONS: Opposing pathologic factors impact spinal cord volume measures in MS. Patients with PPMS demonstrated a trend toward upper cervical cord atrophy. However patients with RRMS showed a trend toward increased volume at the cervical and thoracic levels, which most likely reflects inflammation or edema-related cord expansion. With the disease causing both expansion and contraction of the cord, the specificity of spinal cord volume measures for neuroprotective therapeutic effect may be limited.

Entities:  

Mesh:

Year:  2011        PMID: 21527570      PMCID: PMC3361764          DOI: 10.3174/ajnr.A2459

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  28 in total

Review 1.  Measurement of spinal cord atrophy in multiple sclerosis.

Authors:  Xia Lin; Christopher R Tench; Nikos Evangelou; Timothy Jaspan; Cris S Constantinescu
Journal:  J Neuroimaging       Date:  2004-07       Impact factor: 2.486

2.  MR of the spinal cord in multiple sclerosis: relation to clinical subtype and disability.

Authors:  G J Lycklama à Nijeholt; F Barkhof; P Scheltens; J A Castelijns; H Adèr; J H van Waesberghe; C Polman; S J Jongen; J Valk
Journal:  AJNR Am J Neuroradiol       Date:  1997 Jun-Jul       Impact factor: 3.825

3.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

Review 4.  The measurement and clinical relevance of brain atrophy in multiple sclerosis.

Authors:  Robert A Bermel; Rohit Bakshi
Journal:  Lancet Neurol       Date:  2006-02       Impact factor: 44.182

Review 5.  Clinical-magnetic resonance imaging correlations in multiple sclerosis.

Authors:  Robert Zivadinov; Thomas P Leist
Journal:  J Neuroimaging       Date:  2005       Impact factor: 2.486

6.  Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions.

Authors:  N Evangelou; G C DeLuca; T Owens; M M Esiri
Journal:  Brain       Date:  2004-11-17       Impact factor: 13.501

Review 7.  Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis.

Authors:  David H Miller
Journal:  NeuroRx       Date:  2004-04

8.  Increasing cord atrophy in early relapsing-remitting multiple sclerosis: a 3 year study.

Authors:  W Rashid; G R Davies; D T Chard; C M Griffin; D R Altmann; R Gordon; A J Thompson; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-01       Impact factor: 10.154

9.  Spinal cord atrophy in multiple sclerosis caused by white matter volume loss.

Authors:  Christopher P Gilmore; Gabriele C DeLuca; Lars Bö; Trudy Owens; James Lowe; Margaret M Esiri; Nikos Evangelou
Journal:  Arch Neurol       Date:  2005-12

10.  Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes.

Authors:  Catherine M Dalton; Declan T Chard; Gerard R Davies; Katherine A Miszkiel; Dan R Altmann; Kryshani Fernando; Gordon T Plant; Alan J Thompson; David H Miller
Journal:  Brain       Date:  2004-03-03       Impact factor: 13.501

View more
  17 in total

1.  Five-year longitudinal changes in quantitative spinal cord MRI in multiple sclerosis.

Authors:  Jiwon Oh; Min Chen; Kateryna Cybulsky; Suradech Suthiphosuwan; Estelle Seyman; Blake Dewey; Marie Diener-West; Peter van Zijl; Jerry Prince; Daniel S Reich; Peter A Calabresi
Journal:  Mult Scler       Date:  2020-06-01       Impact factor: 6.312

2.  The relationships among MRI-defined spinal cord involvement, brain involvement, and disability in multiple sclerosis.

Authors:  Adam B Cohen; Mohit Neema; Ashish Arora; Elisa Dell'oglio; Ralph H B Benedict; Shahamat Tauhid; Daniel Goldberg-Zimring; Christian Chavarro-Nieto; Antonella Ceccarelli; Joshua P Klein; James M Stankiewicz; Maria K Houtchens; Guy J Buckle; David C Alsop; Charles R G Guttmann; Rohit Bakshi
Journal:  J Neuroimaging       Date:  2011-03-29       Impact factor: 2.486

3.  Intersubject Variability and Normalization Strategies for Spinal Cord Total Cross-Sectional and Gray Matter Areas.

Authors:  Nico Papinutto; Carlo Asteggiano; Antje Bischof; Tristan J Gundel; Eduardo Caverzasi; William A Stern; Stefano Bastianello; Stephen L Hauser; Roland G Henry
Journal:  J Neuroimaging       Date:  2019-09-30       Impact factor: 2.486

4.  A longitudinal MRI study of cervical cord atrophy in multiple sclerosis.

Authors:  Paola Valsasina; Maria A Rocca; Mark A Horsfield; Massimiliano Copetti; Massimo Filippi
Journal:  J Neurol       Date:  2015-05-01       Impact factor: 4.849

Review 5.  Segmentation of the human spinal cord.

Authors:  Benjamin De Leener; Manuel Taso; Julien Cohen-Adad; Virginie Callot
Journal:  MAGMA       Date:  2016-01-02       Impact factor: 2.310

6.  In vivo imaging of spinal cord atrophy in neuroinflammatory diseases.

Authors:  Winston Liu; Govind Nair; Luisa Vuolo; Anshika Bakshi; Raya Massoud; Daniel S Reich; Steven Jacobson
Journal:  Ann Neurol       Date:  2014-07-22       Impact factor: 10.422

7.  Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis.

Authors:  Regina Schlaeger; Nico Papinutto; Alyssa H Zhu; Iryna V Lobach; Carolyn J Bevan; Monica Bucci; Antonella Castellano; Jeffrey M Gelfand; Jennifer S Graves; Ari J Green; Kesshi M Jordan; Anisha Keshavan; Valentina Panara; William A Stern; H-Christian von Büdingen; Emmanuelle Waubant; Douglas S Goodin; Bruce A C Cree; Stephen L Hauser; Roland G Henry
Journal:  JAMA Neurol       Date:  2015-08       Impact factor: 18.302

8.  2D phase-sensitive inversion recovery imaging to measure in vivo spinal cord gray and white matter areas in clinically feasible acquisition times.

Authors:  Nico Papinutto; Regina Schlaeger; Valentina Panara; Eduardo Caverzasi; Sinyeob Ahn; Kevin J Johnson; Alyssa H Zhu; William A Stern; Gerhard Laub; Stephen L Hauser; Roland G Henry
Journal:  J Magn Reson Imaging       Date:  2014-12-08       Impact factor: 4.813

9.  Spinal cord normalization in multiple sclerosis.

Authors:  Jiwon Oh; Michaela Seigo; Shiv Saidha; Elias Sotirchos; Kathy Zackowski; Min Chen; Jerry Prince; Marie Diener-West; Peter A Calabresi; Daniel S Reich
Journal:  J Neuroimaging       Date:  2014-03-05       Impact factor: 2.486

10.  Cervical and thoracic cord atrophy in multiple sclerosis phenotypes: Quantification and correlation with clinical disability.

Authors:  Yair Mina; Shila Azodi; Tsemacha Dubuche; Frances Andrada; Ikesinachi Osuorah; Joan Ohayon; Irene Cortese; Tianxia Wu; Kory R Johnson; Daniel S Reich; Govind Nair; Steven Jacobson
Journal:  Neuroimage Clin       Date:  2021-04-28       Impact factor: 4.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.